Printer Friendly

THE IMMUNE RESPONSE CORPORATION ANNOUNCES EFFECTIVENESS OF REGISTRATION STATEMENT WITH SEC

 CARLSBAD, Calif., Aug. 10 /PRNewswire/ -- The Immune Response Corporation (NASDAQ-NMS: IMNR) announced today the effectiveness of a Registration Statement recently filed with the Securities and Exchange Commission covering 1,226,144 shares of its common stock. The registration was made in connection with the November 1992 acquisition of TargeTech Inc. At that time the shares were issued to the former securityholders of TargeTech.
 The Immune Response Corporation is a biopharmaceutical company engaged in the development of proprietary products for the treatment of HIV infection, autoimmune diseases and, through TargeTech Inc., gene therapy.
 -0- 8/10/93
 /CONTACT: Bronwyn LeMelle or Cindy Rollins of The Immune Response Corporation investor relations, 619-431-7080/
 (IMNR)


CO: The Immune Response Corporation ST: California IN: MTC SU:

LS-JL -- SD003 -- 1019 08/10/93 08:06 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 10, 1993
Words:130
Previous Article:MORTON'S OF CHICAGO WHETS APPETITES IN CROWD-PLEASING TASTE TEST
Next Article:TRANZONIC ACQUIRES IRONING BOARD MANUFACTURER
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters